A major boost for CSL (ASX:CSL) with the company upgrading its full-year forecast for net profit after tax (NPAT).
The company's share price surged 10 per cent in response to the announcement.
The company previously forecast NPAT growth of 11 per cent (constant currency) in the current financial year, after adjusting for one-off gains and costs associated with the acquisition of the Novartis flu vaccines business.
However, in a statement issued earlier today, the company said following a stronger than expected sales performance in the final three months of last year, led by immunoglobulins and specialty, it now expects to report NPAT of approximately US$800 million for the six months ending 31 December 2016.
It now expects full-year NPAT to increase of 18-20 per cent, including a negative currency impact of around US$20 million.